Resource for Clinical Studies of AKI (Clinical Research/Genomics/Biorepository)

项目总结（见说明）：急性肾损伤（阿基）的临床和转化研究需要精心设计的前瞻性研究，以及获得具有纵向随访的良好特征的患者以及生物样本，使研究者能够探索导致结局的潜在机制和途径。阿基临床研究资源（核心A）的具体目标是：1）提供核心资源，以支持阿基临床研究的设计和实施，2）提供基因组学资源，以进行系统的基因组分析，并允许与临床表型信息相关，以及3）提供与临床和基因组学数据库相链接的生物样品储存库，用于我们的研究者基础的患者表征。该核心将通过已建立的国际合作研究者网络为研究者提供访问阿基患者的途径，这些研究者正在ICU环境中对阿基进行持续登记，目前有1000多名患者，访问生物样本，包括患者和健康对照的DNA以及用于定量评估肾功能变化的方案和工具。自成立以来，核心已成功地支持临床和转化研究的研究人员。核心已经建立了一个强大的数据管理系统和阿基患者数据库，该数据库灵活地适应个体研究者和合作中心的研究目标;目前支持5个大型多中心项目，包括阿基登记研究和药物性肾损伤基因组学的国际前瞻性研究。基因组学资源促进了对阿基遗传决定因素（风险和结局）的研究，并确定了阿基纵向过程的新基因组预测因子。已经进行了超过14，000种生物标志物检测，其中包括20多种分析物，以支持儿科和成人阿基研究。已经建立了一个生物样本库，其中包含来自具有和不具有阿基的良好特征的患者的>2000个连续样本。核心方案为52名调查员（包括4名试点接受者和45名非核心人员）的143个项目提供了支助，产生了57份出版物。这些丰富的资源将继续使阿基的跨学科临床研究能够推进我们对人类阿基的自然史，病理生理学和治疗的理解。核心A与UAB和UCSD的现有资源以及奥布莱恩中心的其他核心相结合，将加速新的研究见解的转化，以改善阿基患者的结局。

PROJECT SUMMARY (See instructions): Clinical and translational research in acute kidney injury (AKI) requires well designed prospective studies as well as access to well characterized patients with longitudinal follow up coupled with biological samples enabling investigators to probe the underlying mechanisms and pathways contributing to outcomes. The specific aims of the Resource for Clinical Studies of AKI (Core A) are to 1) provide core resources to support the design and conduct of clinical research In AKI, 2) provide a genomics resource to perform systematic genomic analyses and allow correlation with clinical phenotypic information, and 3) provide a biological sample repository linked to the clinical and genomics database for the characterization of patients for our investigator base. This core will specifically provide investigators access to patients with AKI through an established international network of collaborating investigators who are contributing to an ongoing registry of AKI in the ICU setting currently with over 1000 patients, access to biological samples including DNA from patients and healthy controls and protocols and tools for quantitative assessment of changes in kidney function. Since its inception the Core has been successful in supporting investigators for clinical and translational research. The Core has established a robust data management system and database of patients with AKI that Is flexible In accommodating the research objectives of individual investigators and collaborating centers; currently supporting 5 large multicenter projects including the AKI registry and an international prospective study for the genomics of drug-induced kidney injury. The genomics resource has facilitated the investigation of genetic determinants (both risk and outcome) of AKI, and identified novel genomic predictors of the longitudinal course in AKI. Over 14,000 biomarker assays incorporating more than 20 analytes have been performed to support both pediatric and adult AKI research. A biological sample repository has been established and has >2000 sequential samples from well-characterized patients with and without AKI. The Core has supported 143 projects for 52 investigators (including 4 pilot recipients and 45 non-core personnel), resulting in 57 publications. These rich resources will continue to enable interdisciplinary clinical investigation in AKI to advance our understanding of the natural history, pathophysiology and treatment of human AKI. Core A in conjunction with existing resources at UAB and UCSD and other cores within the O'Brien center will accelerate the translation of new investigative insights towards improving outcomes for patients with AKI.